Related Experiment Video
Updated: Sep 7, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
Admission Levels of Serum P-Selectin and IL-6 Can Predict Development of Deep Venous Thrombosis in Hospitalized
Nehal Farouk1, Walaa Mohamed Omar Ashry2, Hanan A El-Hagrasy3
1Vascular Surgery Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Insights
Elevated levels of Interleukin-6 (IL-6) and P-selectin are linked to deep venous thrombosis (DVT) in hospitalized COVID-19 patients. These markers may play a role in DVT development during infection.
Area of Science:
- Medical Research
- Infectious Diseases
- Hematology
Background:
- Deep venous thrombosis (DVT) is a frequent complication in COVID-19 patients.
- Elevated levels of Interleukin-6 (IL-6) and P-selectin have been observed in COVID-19.
- The relationship between these markers and DVT in COVID-19 requires further investigation.
Purpose of the Study:
- To evaluate P-selectin and IL-6 levels in COVID-19 patients with DVT.
- To explore the association between these inflammatory markers and clinical/laboratory parameters in COVID-19 patients with DVT.
Main Methods:
- Retrospective study of 150 hospitalized COVID-19 patients.
- Measurement of IL-6 and P-selectin using enzyme-linked immunosorbent assay.
- Diagnosis of DVT via Doppler ultrasound of the lower extremities.
Main Results:
- DVT developed in 39.3% of patients.
- Patients with DVT exhibited significantly higher P-selectin and IL-6 levels (p < 0.001).
- P-selectin and IL-6 demonstrated good performance in identifying DVT (AUCs 0.72-0.86).
- Severe disease, elevated P-selectin, and elevated IL-6 were significant predictors of DVT.
Conclusions:
- Elevated P-selectin and IL-6 levels are likely involved in DVT development in hospitalized COVID-19 patients.
- These markers may serve as potential indicators for DVT risk in this population.
Background And Aim:
Deep venous thrombosis (DVT) of the lower extremities is common in Covid-19 patients. Interleukin (IL)-6 and P-selectin were found to be elevated in Covid-19 patients. The current study aimed to evaluate P-selectin and IL6 in Covid-19 patients with DVT and to explore its relation to clinical and laboratory parameters in those patients.
Patients And Methods:
The present retrospective study included 150 hospitalized COVID-19 patients diagnosed on the basis of a positive result of reverse-transcriptase polymerase chain reaction (RT-PCR) test. Laboratory assessments were included for IL-6 and P selectin assessments via enzyme-linked immunosorbent assay. The primary outcome of the present study was the development of DVT detected by Doppler ultrasound (DU) evaluation of the lower extremities during the admission.
Results:
The present study included 150 hospitalized Covid-19 patients. DVT was developed in 59 patients (39.3%). DVP patients had significantly higher levels of P selectin [76.0 (63.0-87.0) versus 63.0 (54.3-75.0), p < 0.001] and IL-6 [37.0 (27.0-49.0) versus 18.5 (13.5-31.5), p < 0.001]. ROC curve analysis revealed good performance of P selectin [AUC (95% CI): 0.72 (0.64-0.81)] and IL-6 [AUC (95% CI): 0.79 (0.71-0.86)] in identification of DVT. Logistic regression analysis identified the presence of severe disease [OR (95% CI): 9.016 (3.61-22.49), p < 0.001], elevated P selectin [OR (95% CI): 1.032 (1.005-1.059), p = 0.018] and elevated IL-6 [OR (95% CI): 1.062 (1.033-1.091), p < 0.001] as significant predictors of DVT development in multivariate analysis.
Conclusion:
The present study identified a probable role of elevated P-selectin and IL-6 levels in the DVT development in hospitalized Covid-19 patients.
Related Concept Videos
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism I: Introduction

